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Abstract
A small proportion of breast cancers are due to a heritable predisposition. Recently, two
predisposition genes, BRCA1 and BRCA2, have been identified and cloned. The
morphological features of tumours from patients harbouring mutations in the BRCA1 and
BRCA2 genes differ from each other and from sporadic breast cancers. Both are of higher
grade than are sporadic cases. An excess of medullary/atypical medullary carcinoma has been
reported in patients with BRCA1 mutations. Multifactorial analysis, however, shows that the
only features independently associated with BRCA1 mutations are a high mitotic count,
pushing tumour margins and a lymphocytic infiltrate. For BRCA2 mutation, an association
with tubular/lobular carcinoma has been suggested, but not substantiated in a larger Breast
Cancer Linkage Consortium study. In multifactorial analysis, the independent features were
a lack of tubule formation and pushing tumour margins only. The morphological analysis has
implications for clinical management of patients.
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Within the developed countries breast cancer is the com-
monest malignancy in women. It is estimated that approx-
imately one in 12 women will develop breast cancer in
their lifetime.
The majority of breast cancers (95%) are sporadic; only a
small proportion, particularly those diagnosed in young
women, are due to a highly penetrant autosomal-domi-
nant trait. Over the past 5 years there has been consider-
able progress in the identification and localization of the
genes responsible for hereditary breast cancer. Two in
particular have grabbed the headlines; these are BRCA1
and BRCA2 [1,2].
For more than 50 years, researchers have been fascinated
by the association of histopathological cancer type with a
positive family history of breast cancer. Certain types,
including medullary carcinoma, tubular carcinoma, lobular
carcinoma  in situ and invasive lobular carcinoma (Fig.
1a–d), have been reported [3–7] to be found more com-
monly in association with a positive family history of
breast cancer than have other subtypes. Some of the
reported studies have been difficult to interpret because
of the small number of samples, the differing criteria for a
positive family history and the controversies surrounding
the classification of breast cancer. The histopathological
classification of breast disease is subjective and, despite an
attempt to provide clear guidelines, the interobserver vari-
ability is known to be high [8••]. Because of the subjective
nature of histological examination and the factors outlined
above, no clear agreement has emerged that any particular
phenotype is more commonly associated with a positive
family history than any other. Nonetheless, in a histologi-Breast Cancer Research    Vol 1 No 1 Lakhani
32
cal review of the population-based series of 4071 breast
cancers diagnosed in women between the ages of 20 and
54 years in the Cancer and Steroids Hormone study [9],
lobular carcinoma in situ showed a strong association with
familial risk. In the Utah population database [10], inva-
sive lobular carcinoma has been shown to have an associa-
tion with familiality. Since the localization and
identification of breast cancer predisposition genes BRCA1
and BRCA2, pathologists have tried to identify the mor-
phological phenotypes for these two genes.
Histopathological features of BRCA1-
associated tumours
There are a number of reports in the literature [11,12,
13••,14•] that indicate that breast cancers arising in
patients with BRCA1 mutations are of higher grade than
are sporadic cancers. Eisenger et al [14•] studied 27
BRCA1-associated tumours from 14 families and compared
these with sporadic breast carcinomas, matching for grade.
They found an excess of grade III carcinomas in BRCA1-
associated tumours. Marcus et al [13••] reported the first
large series of the pathology of BRCA1-related tumours. In
their study, they assigned 90 breast cancer patients to the
BRCA1 group on the basis of linkage to chromosomes 17q
and/or the presence of ovarian and male breast cancer.
The control set comprised 187 predominantly nonfamilial
breast cancer patients. The tumours were analyzed for his-
tological type, grade, ploidy and S-phase fraction. The
investigators found that BRCA1-associated tumours were
more likely to be of medullary or atypical medullary type,
Figure 1
Histopathological cancer types reported to be associated with a
positive family history of breast cancer. (a) Lobular carcinoma in situ.





and to be of higher grade, were more frequently aneuploid
and had higher tumour cell proliferation rates. The
medullary association lost formal significance when
adjusted for age.
Recently the pathology of breast cancers related to BRCA1
mutations were examined in a very large, collaborative
study organized through the Breast Cancer Linkage Con-
sortium [15••,16••], and the histological findings were
compared with those in control individuals who did not
have a family history of the disease. There were 118 (27%)
patients who were assigned to the BRCA1 group on the
basis of linkage or mutational data. The control group
comprised 548 breast cancer patients who did not have a
known family history. Seven pathologists, all of whom had
experience of breast pathology, carried out the review.
The pathologists were unaware as to whether the slides
were from the familial or sporadic cases. The cancers were
typed and graded using the criteria used by the UK
National Breast Screening Programme [17] as follows.
They were graded by giving a score of 1–3 for each para-
meter. If more than 75% of the tumour has good tubules,
the score is 1; if less than 10% of the tumour has good
tubules, the score is 3. For pleomorphism, the greater the
degree of pleomorphism, the worse the score. Similarly,
the higher the mitotic count per 10 high-power fields, the
higher the score. Total scores of 3–5, 6–7 and 8–9 mean
that the tumour is of grades I, II and III, respectively.
The results from this large review of histopathological
material [15••,16••] produced some intriguing findings. No
differences were found, between BRCA1 and control
breast cancers, in the proportion of the invasive ductal car-
cinoma of no special type. In keeping with the study by
Marcus et al [13••], more carcinomas were recorded as
medullary or atypical medullary in the BRCA1 group
(14%) than in the control group (2%; P<0.0001). The
overall grade for BRCA1 breast cancers was significantly
higher than that in the control population breast cancers
[15••,16••]. Interestingly the higher grade of the BRCA1
tumours was a result of higher score of all three parameters
of grade (tubule formation, pleomorphism and mitosis).
The presence of in-situ disease was also recorded from the
analysis. The results do not represent an accurate assess-
ment of the presence or extent of in-situ disease, because
the breasts of neither the control nor familial patients were
examined extensively. Nevertheless the sampling problem
for the in-situ disease was the same for both familial and
control patients.
Ductal carcinoma in situ was seen less frequently in
BRCA1 cases (41%) than in control individuals (56%;
P=0.01). Lobular carcinoma in situ was also seen less fre-
quently in control individuals, but the results were not sta-
tistically significant.
Because of the strong associations of the medullary and
atypical medullary carcinoma with the BRCA1 phenotype,
a further review to identify the features that were predic-
tive for BRCA1 phenotype was carried out [16•].
Medullary carcinoma is a controversial entity. It is defined
as a tumour that grows in solid sheets within an indistinct
cell border (syncytial growth pattern), has large vesicular
nuclei and prominent nucleoli, a broad pushing margin
and a prominent lymphocytic infiltrate both at the periph-
ery and within the tumour. These features must be
present in the entire tumour for it to be regarded as a clas-
sical medullary carcinoma [17,18•]. If the tumour has less
lymphocytic infiltrate or an infiltrating margin in part of
the tumour, it is regarded as an atypical medullary carci-
noma. The presence of a classical ductal carcinoma of no
special type forming less than 25% of the tumour also
pushes it into an atypical medullary carcinoma category.
Although these features appear to be fairly specific,
pathologists have a great deal of difficulty in making a
diagnosis of medullary and atypical medullary carcinoma,
and, as in this study, the interobserver agreement is low.
Hence, in the second review [16••] the pathologists were
asked to evaluate specific features, rather than assigning a
specific type to the tumour. They were asked to complete
a proforma that included the following: an assessment of
the percentage of tumour present as solid sheets of cells
(<25%, 25–75%, >75%); the total mitotic count per 10
high-power fields; the presence of continuous pushing
margins; the presence of confluent necrosis; the presence
of a lymphocytic infiltrate; and, if present, whether mild or
prominent, the presence of discernible cell borders; the
presence of vesicular nuclei; and the presence of promi-
nent eosinophilic nucleoli.
In a multifactorial analysis using the data from both
reviews [15••,16••], the only factors found to be significant
were total mitotic count, continuous pushing margins, and
lymphocytic infiltrate (Fig. 2 and 3). All other features
including the diagnosis of medullary and atypical
medullary carcinoma were no longer significant in this
multifactorial analysis [16••].
Two of the three features that are independently associ-
ated with cancers from the BRCA1 patient (continuous
pushing margins and lymphocytic infiltrate) are part of the
subset of the characteristics that define medullary carci-
noma. High mitotic count, which is the third feature asso-
ciated with these tumours, is also often seen in medullary
carcinomas, because these tend to be of higher grade, but
it is not regarded as a defining feature. It appears that,
although an increase in the frequency of classical and
atypical medullary carcinoma may contribute to the
observed BRCA1 phenotype, these cancers probably
account for only a small proportion of the differences
observed between those with and those without BRCA1
mutation carriers.Histopathological features of BRCA2-
associated tumours
Unlike BRCA1, data on the pathology of tumours associ-
ated with BRCA2 are limited. The study by Marcus et al
[13••] attempted to delineate the pathology of BRCA2
tumours. Their study groups comprised BRCA1-associated
tumours and ‘others’, which included BRCA2 cases.
Although this latter group included 85 patients, only nine
were linked to BRCA2, and three were of male breast
cancer. The authors suggested that tumours arising in
patients with BRCA2 mutations were different from those
arising in patients with BRCA1 mutations. These tumours
were of lower grade than BRCA1 tumours, were less aneu-
ploid, and did not have the high proliferation seen in
tumours from BRCA1 patients. They found an association
of  BRCA2 tumours with invasive lobular carcinoma,
tubular–lobular carcinoma, tubular carcinoma and cribri-
form carcinoma, which they designated as a ‘tubular–
lobular group’. This is in contrast to the findings of
Agnarsson  et al [19•], who found that BRCA2 tumours in
the Icelandic population were of higher grade than that in
sporadic cases. Their data are, however, based on one par-
ticular BRCA2 mutation – 999del5 – and hence it is not
possible to rule out that this phenotype represents a pecu-
liarity of this particular mutation.
The studies carried out by the Breast Cancer Linkage
Consortium analyzed 78 (18%) patients assigned to the
BRCA2 group [15••]. This represents the largest set of data
on BRCA2 tumours to date. Unlike in the study by Marcus
et al [13••], no difference in the frequency of the invasive
lobular carcinoma or tubular carcinoma between control
individuals and the BRCA2 mutations group was identi-
fied. In fact, no BRCA2 mutations carriers had tubular car-
cinomas, compared with the 5% of the control population.
There was also no evidence of an excess of medullary or
atypical medullary carcinoma in the BRCA2 group [15••].
BRCA2 breast cancers were overall of higher grade than
those from the control population. Interestingly, in con-
trast to BRCA1, the higher grade of BRCA2 tumour was
only due to higher score for tubule formation. No differ-
ences were identified in pleomorphism or mitotic count
between BRCA2 tumours and sporadic cancers.
There was no difference in the incidence of ductal carci-
noma in situ between BRCA2 group and control cancers.
Lobular carcinoma in situ was seen less frequently in
BRCA2 mutation carriers than in control individuals, but
the results were not statistically significant.
Multifactorial analysis from the two reviews performed for
the BRCA2 mutation carriers [16••] showed that the only
significant features were tubule score and continuous
pushing margins.
Conclusion
The studies to date indicate that breast tumours arising in
patients with BRCA1 mutations are different from those
arising in patients with BRCA2 mutations and from non-
familial cancers. The principle differences are in total
mitotic count, tubule formation and lymphocytic infiltrate.
Patients with BRCA2 mutations also have a high rate of
male breast cancer and lower incidence of ovarian cancer.
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Figure 2
Features reported to be predictive for BRCA1 phenotype. (a) Low
power view (×100 magnification) showing the tumour with broad
pushing margin. A prominent lymphoid infiltrate is also seen. (b) High-
power view (×400 magnification) showing the tumour cells with mitotic
activity and the lymphoid infiltrate.
(a) (b)Taken together, the differences in the clinical phenotypes
associated with mutations in the two genes suggests that
the biological activities of the proteins encoded by the
BRCA1 and  BRCA2 genes are probably different.
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